Pfizer, Amgen among 22 majors spreading wings in Hong Kong under investment drive
Sixth batch under OASES initiative also features Boehringer Ingelheim, Hengrui and Haya, with Didi and AutoFlight joining transport push
Global drug maker Pfizer and biotech firm Amgen, each valued at more than HK$1 trillion (US$153 billion), are among 22 strategic enterprises from the fintech, cloud computing and aerial transport sectors to open or expand offices in Hong Kong.
The firms attended a ceremony on Monday to sign agreements with the Office for Attracting Strategic Enterprises (OASES).
It marked the sixth cohort under the government’s flagship investment initiative since its launch, as the South China Morning Post earlier reported.
Financial Secretary Paul Chan Mo-po said 124 strategic enterprises have established operations in the city, promising an expected HK$73 billion in investment and around 25,000 jobs.
“Many enterprises have also chosen to settle in the Northern Metropolis to leverage the proximity and synergy with Shenzhen and other Greater Bay Area cities,” he said at the signing ceremony.
He added that early batches of enterprises have already made a tangible impact, and about 75 per cent of these companies have set up or are establishing their regional or global headquarters in Hong Kong.